Literature DB >> 7625473

Body dysmorphic disorder in the DSM-IV field trial for obsessive-compulsive disorder.

D Simeon, E Hollander, D J Stein, L Cohen, B Aronowitz.   

Abstract

OBJECTIVE: This study investigated the prevalence and phenomenology of body dysmorphic disorder in patients with obsessive-compulsive disorder.
METHOD: The authors studied 442 patients who participated in the DSM-IV field trial for obsessive-compulsive disorder.
RESULTS: Twelve percent (N = 51) of the patients had a lifetime comorbid diagnosis of body dysmorphic disorder. Patients with and without body dysmorphic disorder did not differ in demographic characteristics of obsessive-compulsive symptoms. Patients with obsessive-compulsive disorder and body dysmorphic disorder had more anxious, impulsive, and schizotypal features than patients with obsessive-compulsive disorder alone. Age at onset was similar for the two disorders, and severity correlated. However, insight was significantly more impaired for body dysmorphic disorder than for obsessive-compulsive disorder.
CONCLUSIONS: As previously thought, these findings suggest that the two disorders are strongly related but also have differences that require further investigation.

Entities:  

Mesh:

Year:  1995        PMID: 7625473     DOI: 10.1176/ajp.152.8.1207

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  14 in total

Review 1.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

2.  Delusional versus nondelusional body dysmorphic disorder: clinical features and course of illness.

Authors:  K A Phillips; W Menard; M E Pagano; C Fay; R L Stout
Journal:  J Psychiatr Res       Date:  2005-10-17       Impact factor: 4.791

3.  Associations in the longitudinal course of body dysmorphic disorder with major depression, obsessive-compulsive disorder, and social phobia.

Authors:  Katharine A Phillips; Robert L Stout
Journal:  J Psychiatr Res       Date:  2005-11-23       Impact factor: 4.791

4.  High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors:  W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal:  Neural Plast       Date:  2010-02-18       Impact factor: 3.599

5.  A comparison of insight in body dysmorphic disorder and obsessive-compulsive disorder.

Authors:  Katharine A Phillips; Anthony Pinto; Ashley S Hart; Meredith E Coles; Jane L Eisen; William Menard; Steven A Rasmussen
Journal:  J Psychiatr Res       Date:  2012-07-21       Impact factor: 4.791

6.  Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders.

Authors:  Katharine A Phillips; Anthony Pinto; William Menard; Jane L Eisen; Maria Mancebo; Steven A Rasmussen
Journal:  Depress Anxiety       Date:  2007       Impact factor: 6.505

Review 7.  Recognizing and treating body dysmorphic disorder.

Authors:  Jon E Grant; Katharine A Phillips
Journal:  Ann Clin Psychiatry       Date:  2005 Oct-Dec       Impact factor: 1.567

8.  Body Dysmorphic Symptoms in Youth with Obsessive-compulsive Disorder: Prevalence, Clinical Correlates, and Cognitive Behavioral Therapy Outcome.

Authors:  Þórhildur Ólafsdóttir; Bernhard Weidle; Tord Ivarsson; Davíð R M A Højgaard; Karin Melin; Judith Becker Nissen; Nor Christian Torp; Per Hove Thomsen; Gudmundur Skarphedinsson
Journal:  Child Psychiatry Hum Dev       Date:  2022-01-11

9.  Insight in obsessive compulsive disorder and body dysmorphic disorder.

Authors:  Jane L Eisen; Katharine A Phillips; Meredith E Coles; Steven A Rasmussen
Journal:  Compr Psychiatry       Date:  2004 Jan-Feb       Impact factor: 3.735

Review 10.  Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.